On April 18, Sino Biological Inc., a protein and antibody R&D and production expert, signed a strategic cooperation agreement with Megarobo.

A large population-based cohort study has linked COVID-19 to increased risk of diabetes, adding to the evidence that SARS-CoV-2 infection may contribute to the development of the metabolic disorder.

BioMérieux and JMI Laboratories announced that they have entered a six-year project to evaluate the performance of tests for antimicrobial resistance.

On October 17, 2020, the 22nd meeting of the Standing Committee of the 13th National People's Congress voted to adopt the Biosafety Law, which will come into force on April 15, 2021.

Abbott announced financial results for the first quarter ended March 31, 2023.

The World Health Organization on Wednesday issued a new standard for countries implementing rapid diagnostics to detect tuberculosis. The guidelines are the first-ever WHO has issued for rapid TB testing.

The penetration rate of blood glucose meters among diabetes patients in China is far lower than that in developed countries, and there is a huge market space for blood glucose meters.

UK circulating tumor cell firm Angle said Wednesday that it has signed an agreement with BioView to develop a liquid biopsy HER2 assay using its cell isolation technology, Parsortix, and BioView's automated microscopy systems and software.

Meridian Bioscience said Wednesday the US Food and Drug Administration has cleared the firm's Curian Shiga Toxin immunoassay, expanding the firm's gastrointestinal disease product line.

Berry Genomics recently announced that it will acquire NeoGenomics, a US-based blood testing company, for US$2.4 billion to further strengthen its oncology testing business.

Juntendo University, Sysmex, and ThinkCyte said Tuesday that they are collaborating on research into the early detection and treatment of chronic myelogenous leukemia (CML).

OpGen announced on Tuesday that it has entered into a distribution partnership for its Unyvero A50 system and in vitro diagnostic tests with Fisher Healthcare, a division of Thermo Fisher Scientific.

On April 14, DiaSorin announced that Mr Tony Chan is the President of DiaSorin China. He will also serve as the Chairman of the Board of Directors of DiaSorin China.

Molecular pathology firm Xyall and digital pathology firm Indica Labs said Monday that they have inked a global partnership to combine their technologies to deliver a fully digital and automated workflow for tissue macro dissection for molecular diagnostic testing.

Oxford Nanopore Technologies plc and bioMérieux SA announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.